What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Empagliflozin shows a clear clinical advantage by reducing the combined risk of dying from cardiovascular causes or the likelihood of first hospitalization for heart failure compared to placebo plus standard care. However, the lack of direct comparison with dapagliflozin limits the strength of the evidence.
Does the economic case hold at the expected price? — Cost effectiveness
Empagliflozin is suggested to have similar costs to dapagliflozin, which supports its cost-effectiveness under common thresholds, making it a viable option for treatment.
Is there quality-of-life evidence payers weigh? — Quality of life
The indirect comparison suggests that empagliflozin has a similar effect on quality of life as dapagliflozin, indicating moderate improvements in HRQoL, although specific validated tools were not mentioned.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The document does not highlight significant safety concerns, indicating an acceptable safety profile, although specific adverse effects were not detailed.
Was the drug compared against what payers expect? — Comparator Selection
While empagliflozin was compared to placebo plus standard care, the absence of direct head-to-head trials with dapagliflozin raises concerns about the robustness of the comparator selection.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population appears to be representative of adults with chronic heart failure with preserved or mildly reduced ejection fraction, although subgroup analyses were not explicitly mentioned.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Empagliflozin can be integrated into existing care pathways with minor adjustments, as it is recommended alongside standard care for chronic heart failure.
Are the wider system costs understood? — Resource Use and Cost Implications
The annual treatment cost of empagliflozin is reasonable and aligns with the expected budget impact, indicating a manageable resource use.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on clinical trials, although the lack of direct comparisons introduces some methodological concerns.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are some uncertainties regarding the indirect comparisons, the overall context supports the use of empagliflozin in addressing an unmet need in chronic heart failure.
